secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001628280-26-032097
Event type: m_and_a
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q1 rev $116M, net income $1.4M; lowers FY outlook; exercises Endospan option for ~$135M net
--------------------------------------------------------------------------------

- Q1 revenue $116.3M (+18% GAAP, +12% constant currency YoY); net income $1.4M ($0.03 diluted EPS) vs net loss $0.5M in Q1 2025.
- Adjusted EBITDA $22.1M (+26% YoY); non-GAAP net income $4.2M ($0.08 diluted EPS) vs $2.5M ($0.06) in prior year.
- Full-year 2026 revenue guidance lowered to $480-496M (prev $486-504M); adjusted EBITDA guidance lowered to $100-107M (prev $105-110M).
- Exercised option to acquire Endospan; base price $175M, net ~$135M after offsetting loans; contingent consideration up to $200M; closing expected Q2 2026.
- FDA approved NEXUS Aortic Arch System on April 2, 2026, triggering option exercise; commercial launch planned Jan 1, 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000162828026032097/0001628280-26-032097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000162828026032097/aort-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-032097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer